Recombinant multi-species FTCDNL1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine FTCDNL1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Predicted to enable folic acid binding activity and transferase activity. [provided by Alliance of Genome Resources, Apr 2022]
The Alternative Names of target: FTCDNL1,Formiminotransferase N-terminal subdomain-containing protein,Formiminotransferase-cyclodeaminase N-terminal-like protein,FONG

Target products collectionGo to FTCDNL1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-SE0933-Ab-1/ GM-Tg-hg-SE0933-Ab-2 Human FTCDNL1 protein Human
GM-Tg-rg-SE0933-Ab-1/ GM-Tg-rg-SE0933-Ab-2 Rat FTCDNL1 protein Rat
GM-Tg-mg-SE0933-Ab-1/ GM-Tg-mg-SE0933-Ab-2 Mouse FTCDNL1 protein Mouse
GM-Tg-cynog-SE0933-Ab-1/ GM-Tg-cynog-SE0933-Ab-2 Cynomolgus/Rhesus macaque FTCDNL1 monoclonal antibody Cynomolgus/ Rhesus macaque
GM-Tg-felg-SE0933-Ab-1/ GM-Tg-felg-SE0933-Ab-2 Feline FTCDNL1 protein Feline
GM-Tg-cang-SE0933-Ab-1/ GM-Tg-cang-SE0933-Ab-2 Canine FTCDNL1 protein Canine
GM-Tg-bovg-SE0933-Ab-1/ GM-Tg-bovg-SE0933-Ab-2 Bovine FTCDNL1 protein Bovine
GM-Tg-equg-SE0933-Ab-1/ GM-Tg-equg-SE0933-Ab-2 Equine FTCDNL1 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-SE0933-Ab-1/ GM-Tg-hg-SE0933-Ab-2; GM-Tg-rg-SE0933-Ab-1/ GM-Tg-rg-SE0933-Ab-2;
GM-Tg-mg-SE0933-Ab-1/ GM-Tg-mg-SE0933-Ab-2; GM-Tg-cynog-SE0933-Ab-1/ GM-Tg-cynog-SE0933-Ab-2;
GM-Tg-felg-SE0933-Ab-1/ GM-Tg-felg-SE0933-Ab-2; GM-Tg-cang-SE0933-Ab-1/ GM-Tg-cang-SE0933-Ab-2;
GM-Tg-bovg-SE0933-Ab-1/ GM-Tg-bovg-SE0933-Ab-2; GM-Tg-equg-SE0933-Ab-1/ GM-Tg-equg-SE0933-Ab-2
Products Name FTCDNL1 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name FTCDNL1
Protein Sub-location Secreted Protein/Potential Cytokines
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine FTCDNL1 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.